Renal Denervation Devices Market – Global Industry Analysis, Size, Share, Growth, and Forecast 2021

Renal denervation is a minimal invasive procedure used for the treatment of drug resistant or treatment resistant hypertension. This procedure reduces blood pressure by ablation of renal nerves. With rising incidences of uncontrolled and treatment resistant hypertension, demand for RDN devices is expected to grow in future. Benefits of the RDN procedure such as shorter treatment time and permanent effects over drug treatment, which indirectly reduces the cost of treatment, will also accelerate the market growth. Furthermore, increasing awareness of the RDN process and expected approvals from regulatory bodies such as FDA will boost the demand for RDN devices globally.

WHO estimates indicate that in 2012 more than 1.2 billion people were suffering from hypertension. Clinical data collected from various regions shows the global prevalence of hypertension to be about 38% to 45%. Moreover, new data released by National Health and Nutrition Examination Survey (NHANES) indicates the occurrence of hypertension in the US to be around 30%. After studying data from various clinical studies it is observed that more than 25% to 45% of hypertensive people suffer from uncontrolled hypertension and 15% of these people are observed to have treatment resistant hypertension. This represents a positive outlook for RDN procedure as it considerably reduces the blood pressure in patients with treatment resistant hypertension, thus providing a huge basis for growth of the market.

Download Complete PDF Brochure:

Europe is the largest as well as fastest growing regional market for RDN devices followed by Asia-Pacific. Europe is expected to maintain its dominating position with a strong double digit growth through 2021. The RDN devices market in North America is expected to accelerate due to FDA approvals in the next 4-5 years coupled with the high incidence of lifestyle-related cardiovascular diseases in the region. Aging population along with a high incidence of diabetes will boost the demand for RDN devices in Asia-Pacific, which is estimated to have a large percentage of population that has not even been diagnosed. Large numbers of hypertensive people have not yet been diagnosed with uncontrolled hypertension globally and are still trying many alternate therapies and medications and struggling to control hypertension.

Due to insufficient clinical data, market players are currently struggling to get approvals from regulatory bodies. However, some leading players have received certification by adding innovation to their products coupled with strong research and development activities. Currently, only five devices have received approval for CE mark certification which includes Medtronic’s Symplicity, Boston Scientific’s (Vessix Vascular) V2, St. Jude’s EnligHTN, Covidien’s OneShot and ReCor Medical’s Paradise with not a single RDN therapy receiving approval from the US FDA. Medtronic is the leading player in the RDN devices market and contributes for more than 85% of the global market share. ReCor Medical Paradise is the only ultrasound denervation system that has CE certification. However, in the coming years, a high threat of new entrants is expected with innovative technologies which will reduce procedure time and have greater efficacy. Yet with all the challenges, the renal denervation procedure is considered a boon to treatment of uncontrolled hypertension and thus, the market growth in coming years is expected to be very strong.

Browse Full Research Report:

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.


Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Browse market research blog:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s